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Purpose/Objective: To assess the difference between dosimetry and 
urinary function after I-125 permanent prostate implant monotherapy 
in case a transurethral resection of the prostate (TURP) has been 
performed. 
Materials and Methods: At our institute 818 patients with stage T1a-
T2b prostate cancer, Gleason ≤ 7, received PPI monotherapy (145 Gy), 
from 2007 to 2013. 61 patients underwent a TURP-procedure prior to 
the implant.  
Dosimetry is assessed post-implant at Day 0 and Day 30 (Gold 
Standard). 
Patients urinary function is established by filling in the International 
Prostate Symptom Score sheet to urinary function at follow up 
appointments. 
Results: At Day30 the mean D90: 118.6 vs. 118.3 , V100: 97.4 vs. 96.8 
and U30: 138.6 vs. 137.7 show no significant difference for both 
groups, seed loss is also comparable. 
We observed no significant differences in acute urinary complications 
between the two groups. 
Conclusions: Brachytherapy can be performed in patients who have 
had prior TURP, using accurate ultrasound identification of the 
urethral defect. This results in accurate dosimetry and the same low 
impact on urinary function as in the non-TURP group. 
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Purpose/Objective: A significant drop in blood flow, associated with 
an increase in tumour hypoxia has been shown experimentally 
following the insertion of temporary interstitial catheters into the 
prostate for high doserate (HDR) brachytherapy. In this study, we 
aimed to evaluate multiparametric functional magnetic resonance 
imaging (MRI) for the assessment of changes to the prostate micro-
environment following the insertion of brachytherapy catheters. 
Materials and Method: 6 patients, due to undergo HDR brachytherapy 
as monotherapy for their prostate cancer, underwent multiparametric 
MR imaging before and within 2 hours after the insertion of temporary 
interstitial catheters. The following imaging techniques were used. (1) 
T1-weighted dynamic contrast enhanced imaging (DCE-MRI) to 
evaluate the transfer constant (Ktrans) and the area under the 
gadolinium concentration-time curve (IAUGC60), (2) diffusion-weighted 
MR imaging (DWI) to calculate the apparent diffusion coefficient (ADC) 
and (3) intrinsic susceptibility-weighted T2 imaging (ISW-MRI) to 
calculate the R2* relaxation rate.  
The whole prostate was outlined as the region of interest (ROI) by a 
single radiation oncologist. Voxel-based calculations were performed 
using two bespoke software analysis packages - Magnetic Resonance 
Imaging Workbench for T1-weighted dynamic images & DiffusionView 
for ISW-MRI analysis (both © Institute of Cancer Research, London). 
Results: One patient did not receive intravenous contrast therefore 
DCE-MRI scan analysis could not be conducted. The full data-set is 
shown in table 1. The IAUGC60 & Ktrans values rose in one but fell in 
four patients. Changes in the R2* values ranged from -27% to 26%. 













Table 1 : % change in each MRI parameter before and after catheter
insertion 
Patient R2* Ktrans (min-1) IAUGC60 ADC (mm2 s-1) 
1 -27.3 -49.7 -14.4 2.3 
2 0 -35.6 -7.3 5.1 
3 -2.9 - - 3.8 
4 27.0 -19.7 -0.3 -12.7 
5 -25.9 -11.2 -19.4 3.4 
6 -14.0 74.6 114.3 -4.2 
Average -7.2 -8.4 14.6 -0.4 
 
Conclusions: It is feasible to use DCE-MRI imaging to evaluate changes 
in tissue perfusion immediately following the trauma of brachytherapy 
catheter insertion. However, the highly variable changes in R2* values 
observed in this series may preclude the use of ISW-MRI to assess the 
oxygenation status in the tissue micro-environment. The introduction 
of brachytherapy catheters into the prostate had minimal impact on 
the ADC values; it may therefore be possible to use DWI for tumour 
delineation despite the presence of brachytherapy catheters. Future 
studies that intend to use multiparametric MRI for the evaluation of 
physiological and biological changes within the prostate during or soon 
after HDR brachytherapy should include DCE-MRI and DWI but exclude 
ISW-MRI. 
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Purpose/Objective: The aim of this study is to present dosimetric 
characteristics of CT-based high-dose-rate (HDR) interstitial 
brachytherapy in APBI (Accelerated Partial Breast Irradiation) patients 
treated outside of randomized control trial. Dosimetric and volumetric 
parameters of the treatment plans were evaluated. 
Materials and Methods: From February 2010 to January 2012, 49 
consecutive patients were treated with APBI according to GEC-ESTRO 
recommendations. HDR multi-catheter brachytherapy technique was 
used. Three-, four- and ?ve-plane implants were used in 23, 22 and 4 
patients, respectively. The median number of catheters was 14 
(range, 10-26). The total dose was 32Gy in 4Gy fractions given twice 
daily with minimum 6 hours interval. Postimplant CT scanning was 
done for dose planning. Treatment planning volume (PTV) and organs 
at risk (OAR) were delineated. Geometrical and graphical optimization 
was performed. Dose-volume histograms were calculated for all 
structures in all patients. To quantify the dose distributions the 
following parameters were calculated: volume of the PTV 
(Vptv),percentage of the PTV receiving 90%, 100% and 150% of the 
reference dose (V90, V100 and V150), minimum dose encompassing 
90% of the PTV (D90), the dose non-uniformity ratio (DNR), the dose 
homegenity index (DHI), the conformal index (COIN), maximum dose 
(Dmax) to skin, lung and heart. 
Results: The mean volume of the planning target volume (PTV) was 
55.5 cm3 (range, 19.6-156.6cm3). The average minimum dose received 
by at least 90% of the PTV was 107% (range 87–120%). One patient 
received D90 below 90% because of a pacemaker situated near PTV 
area.The volumes of V90, V100 and V150 were 97%, 94% and 43%. The 
mean values for dose non-uniformity ratio, dose homogeneity index 
and conformal index were 0.39 (range, 0.25-0.55), 0.55 (range, 0.30-
0.73) and 0.65 (range, 0.45-0.82), respectively. The average value of 
maximum doses to skin, lung, and heart were 61%, 36%, and 23%, 
respectively. 
Conclusions: Our analysis showed acceptable dose distribution in 
respect of target coverage and dose to organs at risk in APBI patients 
treated with multi-catheter brachytherapy outside of randomized 
control trial, according to GEC-ESTRO recommendations.  
 
 
